3SBio Inc. (TRSBF)
OTCMKTS
· Delayed Price · Currency is USD
2.223
0.00 (0.00%)
Jun 5, 2025, 8:00 PM EDT
3SBio Revenue
In the year 2024, 3SBio had annual revenue of 9.11B CNY with 16.53% growth. 3SBio had revenue of 4.72B in the half year ending December 31, 2024, with 25.12% growth.
Revenue
9.11B CNY
Revenue Growth
+16.53%
P/S Ratio
4.87
Revenue / Employee
1.63M CNY
Employees
5,577
Market Cap
6.07B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.11B | 1.29B | 16.53% |
| Dec 31, 2023 | 7.82B | 950.20M | 13.84% |
| Dec 31, 2022 | 6.87B | 483.73M | 7.58% |
| Dec 31, 2021 | 6.38B | 794.37M | 14.22% |
| Dec 31, 2020 | 5.59B | 269.55M | 5.07% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
3SBio News
- 10 days ago - Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma - Benzinga
- 19 days ago - Pfizer Thinks Bigger With 3SBio Deal - Seeking Alpha
- 19 days ago - Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China - Investopedia
- 19 days ago - Pfizer strikes deal with China's 3SBio to license cancer drug - CNBC
- 20 days ago - Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal - Benzinga